GeneDx is trading 4.69% down at $63.99, following a regular-session close at $67.14 on October 22, amid broader market weakness.
- No clear company-specific announcement explaining the decline surfaced in available coverage; reported company news was a previously announced long-read sequencing initiative, not a clear catalyst.
- The S&P 500 fell 1.17% and the Nasdaq Composite fell 2.58%. Coverage cited rising oil, geopolitical concerns, tech weakness and worries about AI spending.